Pharmidex are delighted to be one of sixteen partners in an EU Horizon 2020 grant - HeatNMof
April 12, 2022

HeatNMof is a heating-triggered drug release from nanometric metal-organic framework composites

The Initial Training Network HeatNMof aims to develop high quality training opportunities for 12 early-stage-researchers (ESRs) in the area of materials science, advanced characterization and biomedicine.


HeatNMof is training the next generation of materials scientists in nanomedicine to exploit heat-triggered release for delivery of anti-tumour drugs. The network is focusing on one of the most promising classes of nanocomposite carriers, inorganic nanoparticles (iNPs) associated to nanoscaled metal organic frameworks (nanoMOFs).


The successful development of this project, involving seven academic, three industrial partners, six partner organisations (5 universities and 1 company), will contribute to the improvement of the highly societal relevant cancer therapy..


Partners: Fundación IMDEA Energía (Coordinator), Universidad de Santiago de Compostela; Centre National de la Recherche Scientifique; Universiteit Antwerpen; Immaterial Labs Ltd; Institut National des Sciences Appliquees de Toulouse; Universitaet Hamburg; Fondazione Istituto Italiano di Tecnologia.; Nanoscale Biomagnetics SL; Isern Patentes Y Marcas M SL.


- Partner Organisations: Universidad Rey Juan Carlos; Universidad de Zaragoza, University of Cambridge; Universite de Nantes; Universita Degli Studi di Genova; Pharmidex.


Funding Institution/Program: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement Nº 860942.


Call: H2020-MSCA-ITN-2019 (ETN)


https://www.energy.imdea.org/research/projects/heatnmof

📢 Welcome to Pharmidex, Ty Hoffmann!

June 25, 2026
We are pleased to welcome Ty Hoffmann to Pharmidex as our new Business Development Associate (US). Ty recently graduated from Fisher College with a Bachelor’s degree in Cybersecurity and joins us with experience in sales, business development, and client engagement. His background combines commercial awareness with strong analytical and technical skills, making him a great addition to our growing team. As Pharmidex continues to expand its presence across North America, Ty will focus on building new client relationships and supporting organisations seeking high-quality preclinical drug discovery and development services. We are excited to have Ty on board and look forward to supporting his growth and success within the business. Please join us in welcoming him to the Pharmidex team!

Pharmidex team members runs the St Albans Summer Solstice 10K!

June 23, 2026
🏃‍♂️☀️ Congratulations to our Pharmidex team members who took part in the St Albans Summer Solstice 10K #BeatTheSunset ! It was great to see colleagues enjoying a fantastic summer evening while supporting their physical and mental wellbeing. At Pharmidex , we believe health extends beyond the laboratory and activities like these are a great way to stay active, connect with colleagues and have fun. Well done to everyone who took part and represented Pharmidex so positively!

Thanks to our interns from City St George’s, University of London

June 19, 2026
A big thank you to our interns from City St George’s, University of London and heir fantastic contribution to Pharmidex over the past few months. They have supported scientific projects across the business, developed valuable technical skills and gained hands-on experience within a CRO environment. Their contribution has extended beyond the laboratory, helping with our website, marketing materials, conference preparation and business development activities. Science drives success, but communicating that science effectively is just as important. Our interns have helped us do both. Thank you for your hard work, enthusiasm, and dedication. We wish you every success in the next stage of your careers.
More Posts